Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions

1. Uplekar M, Weil D, Lonnroth K, et al. WHO's new end TB strategy. Lancet 2015;385(9979):1799–801 doi: 10.1016/S0140-6736(15)60570-0 25814376

2. Lienhardt C, Glaziou P, Uplekar M et al. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol 2012; 10: 407–16. doi: 10.1038/nrmicro2797 22580364

3. Jamison DT, Summers LH, Alleyne G, et al. Global health 2035: a world converging within a generation. Lancet 2013; 382: 1898–955 doi: 10.1016/S0140-6736(13)62105-4 24309475

4. World Health Organization and Stop TB Partnership. An international roadmap for tuberculosis research. WHO, Geneva, 2011. http://www.stoptb.org/assets/documents/resources/publications/technical/tbresearchroadmap.pdf

5. Sizemore C et al. The role of biomedical research in global tuberculosis control: gaps and challenges. Emerging Microbes and Infections (2012) 1, e9; doi: 10.1038/emi.2012.21 26038420

6. Russell DG, Barry CE 3rd, Flynn JL. Tuberculosis: what we don’t know can, and does hurt us. Science 2010; 328: 852 doi: 10.1126/science.1184784 20466922

7. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al and TBNET. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009;33:956–73. doi: 10.1183/09031936.00120908 19407047

8. Esmail H, Barry CE 3rd, Wilkinson RJ. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today 2012; 17: 514–521. doi: 10.1016/j.drudis.2011.12.013 22198298

9. World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization (WHO/HTM/TB/2015.22), 2015. http://www.who.int/tb/publications/global_report/en/

10. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J. 2013 Jul;42(1):252–71. doi: 10.1183/09031936.00157212 23180585

11. UNITAID. Tuberculosis. Diagnostic technology and market landscape, 3rd Edition. http://www.unitaid.eu/images/marketdynamics/publications/UNITAID_TB_Diagnostics_Landscape_3rd-edition.pdf

12. Kik SV et al. Tuberculosis diagnostics: which target product profiles should be prioritised? Eur Respir J 2014; 44(2):537–40. doi: 10.1183/09031936.00027714 24696110

13. World Health Organization. Consensus meeting on high-priority target product profiles, 28–29th April 2014. Geneva, World Health Organization, 2014. http://www.who.int/tb/laboratory/resource/en/

14. Hamilton CD, Swaminathan S, Christopher DJ, et al. RePORT International: advancing tuberculosis biomarker research through global collaboration. Clin Infect Dis. 2015 Oct 15;61Suppl 3:S155–9.

15. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223. 15591164

16. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3(11):e466. doi: 10.1371/journal.pmed.0030466 17132069

17. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim policy guidance. Geneva, World Health Organization; 2013. (WHO/HTM/TB/2013.6). http://www.who.int/tb/challenges/mdr/bedaquiline/en/

18. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis: Interim policy guidance. Geneva: World Health Organization; 2014. (WHO/HTM/TB/2014.23). http://www.who.int/tb/features_archive/delamanid/en/

19. Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infectious Diseases 2014;14: 327–40 doi: 10.1016/S1473-3099(13)70328-1 24670627

20. Phillips PP, Gillespie SH, Boeree M, et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis. 2012 May 15;205 Suppl 2:S250–7. doi: 10.1093/infdis/jis041 Epub 2012 Mar 22. 22448027

21. Kaufmann SH, Lange C, Rao M, et al. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. Lancet Resp Med. 2014;2(4):301–20.

22. Evans TG et al. Preventive vaccines for tuberculosis. Vaccine; 2013,31S: B223–B226.

23. Brennan MJ and Thole J, Eds. Tuberculosis vaccines: A strategic blueprint for the next decade. Tuberculosis. 2012; 92: Supplement 1; S6–S13.

24. Lienhardt C, Cobelens F. Operational research for TB control: the scope, the needs and the way forward. Int J Tuberc Lung Dis, 2011, 15(1):6–13. 21276290

25. Lönnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010–50: cure, care, and social development. Lancet, 2010, 375(9728):1814–29 doi: 10.1016/S0140-6736(10)60483-7 20488524

26. Lönnroth K, Jaramillo E, Williams BG, et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009; 68: 2240–2246. doi: 10.1016/j.socscimed.2009.03.041 19394122

27. Murray M, Oxlade O, Lin HH. Modeling social, environmental and biological determinants of tuberculosis. Int J Tuberc Lung Dis 2011; 15 Suppl 2: S64–S70. doi: 10.5588/ijtld.10.0535 21740661

28. Tameris MD1, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013 Mar 23;381(9871):1021–8. 23391465

29. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis N Engl J Med. 2014 Oct 23;371(17):1588–98. doi: 10.1056/NEJMoa1315817 25337748

30. Gillespie SH1, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1577–87. doi: 10.1056/NEJMoa1407426 Epub 2014 Sep 7. 25196020

31. Jindani A1, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis Rifaquine trial N Engl J Med. 2014 Oct 23;371(17):1599–608. doi: 10.1056/NEJMoa1314210 25337749

32. Treatment Action Group: 2015 Report on Tuberculosis Research Funding Trends, 2005–2014: A Decade of Data. TAG, New York, 2015.

33. Stop TB Partnership. Global Plan to Stop TB 2011–2015. WHO, Geneva, 2010.

34. Dye C and Williams B.G. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface. 2008 Jun 6;5(23):653–62. 17690054

35. World Health Organization. Documentation for World Health Assembly 67. http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_11-en.pdf

36. Lienhardt C. Fundamental research is the key to eliminating TB. Nature. 2014 Mar 27; 507(7493): 401. doi: 10.1038/507401a 24670725

37. Kritski AL et al. Two decades of research on tuberculosis in Brazil: state of the art of scientific publications. Revista de Saúde Pública, 2007;41 (Suppl):9–14.

38. South African TB Vaccine Initiative (SATVI) - http://www.satvi.uct.ac.za/

39. Bates I et al. Evaluating health research capacity building: an evidence-based tool. PLoS Med. 2006; 3(8):e299. doi: 10.1371/journal.pmed.0030466 16942394

40. Bates I et al. Indicators of sustainable capacity building for health research: analysis of four African case studies. Health Research Policy and Systems, 2011;28;9(1):14: doi: 10.1186/1478-4505-9-14

41. EDCTP. New EDCTP programme celebrated in Cape Town, South Africa on 2 December 2014. 2 December 2014. http://www.edctp.org/news/new-edctp-programme-celebrated-cape-town-south-africa-2-december-2014-2/.

42. Stop TB Partnership. BRICS Health Ministers make historic commitment and agree to cooperation plan on TB at BRICS Ministers of Health Meeting in Brazil. 6 December 2014. http://www.tbonline.info/posts/2014/12/6/brics-health-ministers-make-historic-commitment-an/.

43. World Health Organization. Global Action Framework for TB Research in support of the Third Pillar of WHO’s End TB Strategy. Geneva, World Health Organization; 2015. (WHO/HTM/TB/2015.26). http://www.who.int/tb/features_archive/global_framework_research/en/